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February 2016 Abstracts S13CTLA-4 and PD-1 axis has changed treatment and
prognosis of diverse cancers. In addition, these de-
velopments have prompted the need to understand the
immunobiology of tumors and design the optimal cur-
rent and future therapies combining immune and non-
immune mechanisms. This progress is also accompanied
with new challenges. Possibly, two of the most critical
questions in the ﬁeld include: i) the establishment and
reﬁnement of strong predictive biomarkers and ii) the
identiﬁcation of additional non-redundant immune
inhibitory targets to treat patients with the so-called
“non-inﬂammed” tumors lacking prominent pre-existing
tumor immune inﬁltration.
Blockade of the PD-1/PD-L1 axis induces prominent
and lasting clinical responses in w20% of patients
with non-small cell lung cancer (NSCLC). Recent
studies have shown also an adequate safety proﬁle
and signiﬁcant clinical advantage of these therapies
over more traditional chemotherapy agents. The suc-
cess of these therapies uncovered the power of
blocking immune inhibitory signals that are enriched
in the tumor microenvironment. Because of the
prominent but numerically low proportion of patients
showing objective beneﬁt form PD-1 blockade, devel-
opment of predictive biomarkers is needed to reduce
overtreatment and costs associated with these com-
pounds. Diverse studies have found that expression of
PD-L1 by immunohistochemistry (IHC) and pre-exis-
tence of tumor inﬁltrating lymphocytes (TILs) are
associated with beneﬁt to these therapies, supporting
the notion that a pre-existing anti tumor immune
response is required for immune re-invigoration using
PD-1 axis blockers. However the predictive value of
IHC assays is limited and there are different PD-L1
test available that have not been standardized or
tested for equivalence. To date, only one PD-L1 IHC
assay (22C3) has been approved as companion
biomarker for PD-1 blockade in NSCLC. Recently, it
was reported that the total mutational burden or
predicted neo-antigen load detected by whole exome
sequencing analysis has the potential to inform about
the likelihood of response to the anti PD-1 compound
pembrolizumab in advanced NSCLC. However, this test
requires validation as a biomarker, standardization
and the use of sophisticated sequencing and bioin-
formatics resources that are not available in most non-
academic institutions. Inﬂammation, interferon-gamma
(IFN-g) related mRNA-based signatures and T-cell
receptor sequencing have also recently been suggested
to have association with response to PD-1 blockade.
However, their predictive value has not been demon-
strated in lung cancer and their systematic measure-
ment represents a technical challenge. Integration and
reﬁnement of available immunotherapy biomarkerscould provide optimal use of immunostimulatory
therapies in lung cancer.Impact of co-mutations on the
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Activating mutations in KRAS account for the most
prevalent molecularly deﬁned subset of lung adeno-
carcinoma (LUAC), yet therapeutic strategies aimed at
targeting KRAS-mutant lung tumors have achieved
limited clinical success. Breaking immune tolerance
with inhibitors of immune checkpoints, particularly
those involving the PD-1/PD-L1 axis, has emerged as a
novel paradigm in the treatment of NSCLC, leading to
the recent FDA approval of nivolumab and pem-
brolizumab. It has been postulated that KRAS-mutant
LUAC may be particularly amenable to immuno-
therapy; however, heterogeneous clinical responses
have been observed in clinical trials. We have recently
identiﬁed co-occurring genetic events as major de-
terminants of the molecular diversity of KRAS-mutant
LUAC. Speciﬁcally, KRAS-mutant lung tumors can be
segregated into three major subgroups that are
dominated, respectively, by co-occurring genetic
alterations in STK11/LKB1 (KL), TP53 (KP) and
CDKN2A/B, the latter coupled with low expression of
the TTF1 transcription factor (KC). Co-mutation
deﬁned subsets exhibit distinct biological behavior,
variable phenotypic characteristics and unique thera-
peutic vulnerabilities.
Importantly, KRAS co-mutations can also impact the
tumor immune micro-environment and may thus pro-
mote mechanisms of immune evasion that are speciﬁc to
the tumor oncogenotype. We have identiﬁed that inac-
tivation of the LKB1 serine/threonine kinase, a master
regulator or cellular bio-energetics and polarity, is
associated with a “cold” immune micro-environment
across several datasets of both chemotherapy-naïve and
platinum-refractory LUAC. This is characterized by low
densities of intra-tumoral CD3+ and CD8+ lymphocyte
sub-populations and low expression of PD-L1-positive
tumor and non-tumor cells. The mechanistic basis of this
ﬁnding as well as its implications for therapy with
S14 Journal of Thoracic Oncology Vol. 11 No. 2Simmune checkpoint inhibitors are currently under active
investigation.
Oncogenic KRAS regulates asparagine
synthaseDana Gwinn, Eric Alejandro Sweet-Cordero
Stanford University, Stanford, CAKras is a small GTPase that functions in the trans-
mission of extracellular mitogenic stimuli, and is one of
the most frequently mutated genes in non-small cell
lung cancer (NSCLC). Previously, Kras has been
demonstrated to play a role in tumor metabolism in
certain cell types and cancers, but this has yet to be
analyzed in the context of NSCLC. We have analyzed
how Kras changes metabolic gene expression by
expressing a doxycycline-inducible hairpin against
Kras in several NSCLC cell lines. One of the most
regulated metabolism genes is asparagine synthetase
(Asns), which transfers the g-amino group of glutamine
to aspartate, yielding glutamate and asparagine. We
ﬁnd elevated levels of Asns in Kras mutant tumors, and
that expression of Asns correlates with poor patient
outcome. Knockdown of Asns in the absence of exog-
enous asparagine in the media results in inhibition of
cell growth and induction of apoptosis that is rescued
by addition of asparagine. Additionally, under condi-
tions of low glutamine levels, knockdown of Asns
sensitizes cells to apoptosis, and overexpression of
Asns is protective under these conditions. We also ﬁnd
a role for the glutaminase-activity of Asns in glutamine-
mediated anapleurosis of the TCA cycle. These obser-
vations suggest Asns may be an interesting and novel
therapeutic target for NSCLC tumors with mutations in
Kras.
Blood-based biomarkers for lung
cancer: Ready for prime time?Anil Vachani University of Pennsylvania,
Philadelphia, PABlood based biomarkers have the potential for
improving outcomes in lung cancer, a disease where
approximately 40% of patients present with distant
metastases at diagnosis. Two important areas of
research include the discovery of risk biomarkers (e.g.
deﬁning who will develop lung cancer in the future) and
the identiﬁcation of diagnostic biomarkers for use as a
screening tool or to assess the likelihood of cancer in
patients with a radiographic abnormality such as a lung
nodule. Although the pace of biomarker discovery isadvancing rapidly across all of these areas, the devel-
opment of biomarkers to assess the likelihood of cancer
in patients with lung nodules has been an intense area of
research and several biomarkers are currently being
evaluated in prospective trials.
Lung nodules are increasingly identiﬁed either inci-
dentally or through the use of screening low dose chest
CT. Lung nodules deemed indeterminate lack the fea-
tures suggestive of benign etiologies and present clini-
cians with a diagnostic conundrum. Although most lung
nodules are benign, patients frequently undergo multiple
diagnostic tests, including the use of positron emission
tomography (PET), as well as invasive procedures such
as transthoracic needle aspiration, bronchoscopy and/or
surgery. Therefore, biomarker strategies to distinguish
between malignant and benign lung nodules may miti-
gate the diagnostic burden faced in this setting.
Peripheral blood based detection strategies are an
attractive approach for diagnostic markers, given the
ease of acquisition and potential for serial testing, and
are based on the underlying hypothesis that molecular
alterations of tumor cells lead to the synthesis of distinct
molecular species that can be detected in the blood.
Peripheral blood biomarkers have been identiﬁed in
both the cellular component (circulating tumor cells,
white blood cells) and in the non-cellular fraction (e.g.
plasma, serum), and studies have spanned across several
different types of molecular species.
The presentation will review the rationale for the use
of early detection biomarkers for risk assessment,
screening, and diagnosis, and provide a comprehensive
overview of blood based biomarkers currently in
development, including markers that are available for
clinical use. This will include an analysis of existing data
from clinical validation and utility studies supporting the
use of blood based diagnostic tests as well as a discus-
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The CRISPR/Cas9 bacterial system uses short non-cod-
ing RNAs as an adaptive defense mechanism against
invading DNAs. This system has recently been adapted
as a tool to edit mammalian genomes, and requires only
the co-expression of the Cas9 endonuclease and a short
guide RNA that can direct it to target loci.
